Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02034344
Other study ID # CR102355
Secondary ID NOCOMPOUNDLUP000
Status Completed
Phase Phase 0
First received December 10, 2013
Last updated December 15, 2016
Start date October 2013
Est. completion date May 2015

Study information

Verified date December 2016
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardGermany: Ethics CommissionUnited States: Food and Drug AdministrationUnited States: State Food and Drug AdministrationUSA: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to obtain skin, blood, and urine samples from patients with active cutaneous lupus lesions and from healthy participants.


Description:

This is a Phase 0 multi-center and longitudinal study of biomarkers and clinical parameters in patients with lupus erythematosus (LE). Approximately 80 participants (20 healthy participants and 60 patients with LE) will be enrolled. This will include 30 with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE), and 30 with DLE/SCLE with SLE. All patients with LE will continue to be managed by their personal physicians per their standard-of-care. Study participants will undergo interventional procedures that include collection of urine, blood samples and skin biopsy. There will be a single sample collection timepoint for healthy participants and two sample collection timepoints for LE patients, separated by approximately 12 weeks. A blood sample for genomic analysis will be collected for research purposes from patients who provide consent and where local regulations permit. The data obtained in this study will be used in the evaluation of new therapies for lupus and may help in developing new treatments. Safety evaluations will include assessment of adverse events, clinical laboratory tests, vital signs, and physical examinations. The total duration of study participation will be approximately 11 days for healthy participants and 95 days for patients with LE.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Have Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) with or without a diagnosis of Systemic Lupus Erythematosus (SLE)

- Active DLE or active SCLE confirmed by histological analysis (for participants with DLE or SCLE without SLE)

- Confirmed diagnosis of SLE using American College of Rheumatology criteria and has current or historical positive antinuclear antibodies (ANA) or anti double-stranded deoxyribonucleic acid (anti-dsDNA) (for participants with DLE or SCLE with SLE)

- An active skin lesion that can be biopsied (for participants with lupus erythematosus)

Exclusion Criteria:

- Known or thought to have a diagnosis of drug-induced lupus

- An active skin disease that is not a manifestation of lupus erythematosus

- Has an acute cutaneous lupus erythematosus rash only

- If taking anti-malarial therapy has not been on a stable dose for at least 8 weeks before Day 1

- Participants treated with greater than 10mg/day of prednisone therapy or equivalent in the last 4 weeks prior to Day 1

- Positive serology for human immunodeficiency virus antibody, hepatitis B virus, or hepatitis C virus

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Procedure:
Skin biopsy
Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
Blood collection
Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
Urine collection
Urine will be collected from all participants.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Germany,  Mexico,  Poland,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The concentration of individual serum biomarkers Investigation of pathways which may be dysregulated in cutaneous lupus lesions Day 1 (for healthy participants); Day 1 and Day 84 (for participants with lupus erythematosus) No
Secondary The concentration of individual urine biomarkers The presence of potential biomarkers of disease activity will be explored in urine. Day 1 (for healthy participants); Day 1 and Day 84 (for participants with lupus erythematosus) No
Secondary The concentration of individual skin biomarkers The presence of potential biomarkers of disease activity will be explored in blood. Day 1 (for healthy participants); Day 1 and Day 84 (for participants with lupus erythematosus) No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1